Literature DB >> 18378543

The clinical approach towards chondrosarcoma.

Hans Gelderblom1, Pancras C W Hogendoorn, Sander D Dijkstra, Carla S van Rijswijk, Augustinus D Krol, Antonie H M Taminiau, Judith V M G Bovée.   

Abstract

This review provides an overview of the histopathology, classification, diagnostic procedures, and therapy of skeletal chondrosarcoma. Chondrosarcomas that arise de novo are primary chondrosarcomas, whereas chondrosarcomas developing superimposed on pre-existing benign cartilage neoplasms such as enchondromas or osteochondromas are referred to as secondary chondrosarcomas. Conventional chondrosarcomas can be categorized according to their location in bone into central, peripheral, and juxtacortical chondrosarcomas. Histological grading is related to prognosis; however, it is also subject to interobserver variability. Rare subtypes of chondrosarcoma, including dedifferentiated, mesenchymal, and clear cell chondrosarcoma, are discussed as well. Magnetic resonance imaging is necessary to delineate the extent of the intraosseous and soft tissue involvement preoperatively. Computed tomography is especially recommended in the pelvis and other flat bones where it may be difficult to discern the pattern of bone destruction and the presence of matrix mineralization. Wide, en-bloc excision is the preferred surgical treatment in intermediate- and high-grade chondrosarcoma. In low-grade chondrosarcoma confined to the bone, extensive intralesional curettage followed by local adjuvant treatment and filling the cavity with bone graft has promising long-term clinical results and satisfactory local control. Chondrosarcomas are relatively radiotherapy resistant; therefore, doses >60 Gy are needed in attempts to achieve local control after incomplete resection. Irradiation with protons or other charged particles seems beneficial in this curative situation. Chemotherapy is only possibly effective in mesenchymal chondrosarcoma, and is of uncertain value in dedifferentiated chondrosarcoma. Potential new systemic treatment targets are being discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18378543     DOI: 10.1634/theoncologist.2007-0237

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  203 in total

Review 1.  Imaging features of primary and secondary malignant tumours of the sacrum.

Authors:  E Thornton; K M Krajewski; K N O'Regan; A A Giardino; J P Jagannathan; N Ramaiya
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

Review 2.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

Review 3.  Therapeutic molecular targets in human chondrosarcoma.

Authors:  Nuor Jamil; Sarah Howie; Donald M Salter
Journal:  Int J Exp Pathol       Date:  2010-10       Impact factor: 1.925

4.  Primary thoracic chondrosarcoma with intra-abdominal extension in a renal transplant recipient: A case report.

Authors:  Dimitrios Giannis; Dimitrios Moris; Brian Ishum Shaw; Spyridon Vernadakis
Journal:  Mol Clin Oncol       Date:  2020-04-24

5.  Chondroblastoma in adult age.

Authors:  Andrea Angelini; Mohammad Hassani; Andreas F Mavrogenis; Giulia Trovarelli; Carlo Romagnoli; Antonio Berizzi; Pietro Ruggieri
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-06-20

6.  Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies.

Authors:  Caroline Peyrode; Valérie Weber; Emmanuelle David; Aurélien Vidal; Philippe Auzeloux; Yves Communal; Marie Mélanie Dauplat; Sophie Besse; François Gouin; Dominique Heymann; Jean Michel Chezal; François Rédini; Elisabeth Miot-Noirault
Journal:  Invest New Drugs       Date:  2011-04-16       Impact factor: 3.850

7.  Downregulation of miR-185 and upregulation of miR-218 expression may be potential diagnostic and prognostic biomarkers of human chondrosarcoma.

Authors:  Peyman Karimi Goudarzi; Afshin Taheriazam; Saeid Asghari; Mohammad Jamshidi; Mohammadreza Shakeri; Emad Yahaghi; Alireza Mirghasemi
Journal:  Tumour Biol       Date:  2015-09-18

8.  Clinical significance of traditional clinical parameters and inflammatory biomarkers for the prognosis of patients with spinal chondrosarcoma: a retrospective study of 150 patients in a single center.

Authors:  Kehan Xu; Bo Li; Quan Huang; Dongjie Jiang; Haitao Sun; Nanzhe Zhong; Wei Wan; Haifeng Wei; Jianru Xiao
Journal:  Eur Spine J       Date:  2019-05-04       Impact factor: 3.134

9.  Cervical chondrosarcoma- rare malignancy: a case report.

Authors:  Shuaib Merchant; S M Azeem Mohiyuddin; Satish Rudrappa; R P Deo; Sagayaraj A; Lakshmi R Menon
Journal:  Indian J Surg Oncol       Date:  2014-09-14

10.  Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.

Authors:  Tyler J Bradshaw; Stephen R Bowen; Ngoneh Jallow; Lisa J Forrest; Robert Jeraj
Journal:  J Nucl Med       Date:  2013-09-16       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.